Pharma-Bio Serv Debt-to-EBITDA Ratio Growth & History (PBSV)
Pharma-Bio Serv's debt-to-ebitda ratio was 0.30 for fiscal 2023.
View full Pharma-Bio Serv company overviewPharma-Bio Serv annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-10-31 | 0.30 | −0.10 | −25.21% |
| 2022 | 2022-10-31 | 0.40 | — | — |
| 2020 | 2020-10-31 | 0.37 | 0.33 | +755.23% |
| 2019 | 2019-10-31 | 0.04 | — | — |
| 2016 | 2016-10-31 | 0.24 | 0.20 | +573.36% |
| 2015 | 2015-10-31 | 0.03 | 0.01 | +17.09% |
| 2014 | 2014-10-31 | 0.03 | 0.02 | +128.19% |
| 2013 | 2013-10-31 | 0.01 | −0.01 | −35.80% |
| 2012 | 2012-10-31 | 0.02 | −0.01 | −37.71% |
| 2011 | 2011-10-31 | 0.03 | −0.04 | −57.73% |
| 2010 | 2010-10-31 | 0.08 | — | — |
Pharma-Bio Serv quarterly debt-to-ebitda ratio
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2024 | 2024-01-31 | 5.21 | 4.84 | +1282.22% |
| Q4 2023 | 2023-10-31 | 0.30 | −0.10 | −25.21% |
| Q3 2023 | 2023-07-31 | 0.28 | — | — |
| Q2 2023 | 2023-04-30 | 0.32 | — | — |
| Q1 2023 | 2023-01-31 | 0.38 | — | — |
| Q4 2022 | 2022-10-31 | 0.40 | — | — |
| Q3 2021 | 2021-07-31 | 0.59 | 0.24 | +69.50% |
| Q2 2021 | 2021-04-30 | 0.45 | 0.00 | +1.03% |
| Q1 2021 | 2021-01-31 | 0.39 | −0.12 | −23.66% |
| Q4 2020 | 2020-10-31 | 0.37 | 0.33 | +755.23% |
| Q3 2020 | 2020-07-31 | 0.35 | 0.31 | +718.67% |
| Q2 2020 | 2020-04-30 | 0.44 | 0.40 | +1088.28% |
| Q1 2020 | 2020-01-31 | 0.52 | 0.48 | +1511.97% |
| Q4 2019 | 2019-10-31 | 0.04 | — | — |
| Q3 2019 | 2019-07-31 | 0.04 | — | — |
| Q2 2019 | 2019-04-30 | 0.04 | — | — |
| Q1 2019 | 2019-01-31 | 0.03 | — | — |
| Q4 2016 | 2016-10-31 | 0.24 | 0.20 | +573.36% |
| Q3 2016 | 2016-07-31 | 0.05 | 0.01 | +45.68% |
| Q2 2016 | 2016-04-30 | 0.03 | 0.00 | +7.77% |
| Q1 2016 | 2016-01-31 | 0.03 | −0.00 | −4.16% |
| Q4 2015 | 2015-10-31 | 0.03 | 0.01 | +17.09% |
| Q3 2015 | 2015-07-31 | 0.03 | −0.00 | −11.88% |
| Q2 2015 | 2015-04-30 | 0.03 | −0.00 | −1.67% |
| Q1 2015 | 2015-01-31 | 0.03 | 0.02 | +168.79% |
| Q4 2014 | 2014-10-31 | 0.03 | 0.02 | +128.19% |
| Q3 2014 | 2014-07-31 | 0.04 | 0.02 | +142.84% |
| Q2 2014 | 2014-04-30 | 0.03 | 0.02 | +95.01% |
| Q1 2014 | 2014-01-31 | 0.01 | −0.01 | −35.09% |
| Q4 2013 | 2013-10-31 | 0.01 | −0.01 | −35.80% |
| Q3 2013 | 2013-07-31 | 0.01 | −0.00 | −14.66% |
| Q2 2013 | 2013-04-30 | 0.02 | −0.00 | −19.16% |
| Q1 2013 | 2013-01-31 | 0.02 | −0.01 | −24.24% |
| Q4 2012 | 2012-10-31 | 0.02 | −0.01 | −37.71% |
| Q3 2012 | 2012-07-31 | 0.02 | — | — |
| Q2 2012 | 2012-04-30 | 0.02 | — | — |
| Q1 2012 | 2012-01-31 | 0.03 | — | — |
| Q4 2011 | 2011-10-31 | 0.03 | — | — |
Pharma-Bio Serv debt-to-ebitda ratio trends
Between the periods ended 2010-10-31 and 2023-10-31, Pharma-Bio Serv's debt-to-ebitda ratio increased from 0.08 to 0.30, a change of 0.22. The latest reported quarter, Q1 2024, shows 5.21.
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharma-Bio Serv source filings ↗